Document is current
Any future updates will be listed below
-
Authors
Koltai, Mihaly http://orcid.org/0000-0002-7341-5114
Moyes, Jocelyn
Nyawanda, Bryan
Nyiro, Joyce
Munywoki, Patrick K.
Tempia, Stefano
Li, Xiao
Antillon, Marina
Bilcke, Joke
Flasche, Stefan
Beutels, Philippe
Nokes, D. James
Cohen, Cheryl
Jit, Mark
-
Funding
Funding for this research was provided by:
Bill and Melinda Gates Foundation (INV-007610)
- License Information
-
More Information
Article History
Received: 11 September 2022
Accepted: 22 February 2023
First Online: 31 March 2023
Declarations
:
: The study received an ethics approval under the name ‘<i>Cost effectiveness analysis for RSV disease interventions in Kenya and South Africa</i>’ from the Observational Research Ethics Committee of the <i>London School of Hygiene & Tropical Medicine</i>, LSHTM Ethics Reference number: 22670. Local ethical approvals for this study’s analyses were obtained from KEMRI (Kenya; reference number SERU 3939) and the University of the Witwatersrand, Johannesburg (South Africa; reference number M121195), respectively. This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy [Project ID: 0900f3eb81f6f11c].
: All co-authors consented to the publication of the study.
: PB, XL, and JB report grants from the European commission public-private IMI projects RESCEU and PROMISE and PB reports grants from Pfizer and Merck (outside of the current work).
